Steven C Plaxe

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Epidemiology of low-grade serous ovarian cancer
    Steven C Plaxe
    Division of Gynecologic Oncology, Department of Reproductive Medicine, Rebecca and John Moores University of California, San Diego, Cancer Center, San Diego, CA, USA
    Am J Obstet Gynecol 198:459.e1-8; discussion 459.e8-9. 2008
  2. ncbi request reprint Use of psychosocial services increases after a social worker-mediated intervention in gynecology oncology patients
    Yuko Abbott
    Department of Reproductive Medicine, University of California, San Diego, Moores Cancer Center, La Jolla, CA 92093, USA
    Health Soc Work 38:113-21. 2013
  3. doi request reprint Women with gynecologic malignancies have a greater incidence of suicide than women with other cancer types
    Kristy K Ward
    Department of Reproductive Medicine, Division of Gynecologic Oncology, Rebecca and John Moores UCSD Cancer Center, La Jolla, CA 92093 0987, USA
    Suicide Life Threat Behav 43:109-15. 2013
  4. pmc Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression
    Kristy K Ward
    Department of Reproductive Medicine, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
    Clin Exp Metastasis 30:579-94. 2013
  5. doi request reprint Changing demographics of cervical cancer in the United States (1973-2008)
    Kristy K Ward
    Rebecca and John Moores UCSD Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, La Jolla, CA, USA
    Gynecol Oncol 126:330-3. 2012
  6. ncbi request reprint Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study
    Steven C Plaxe
    Department of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA
    Gynecol Oncol 84:32-5. 2002
  7. ncbi request reprint Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study
    Steven C Plaxe
    Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California San Diego Medical Center, 402 Dickinson Street, San Diego, CA 92103 8433, U S A
    Am J Clin Oncol 25:45-7. 2002

Collaborators

Detail Information

Publications7

  1. doi request reprint Epidemiology of low-grade serous ovarian cancer
    Steven C Plaxe
    Division of Gynecologic Oncology, Department of Reproductive Medicine, Rebecca and John Moores University of California, San Diego, Cancer Center, San Diego, CA, USA
    Am J Obstet Gynecol 198:459.e1-8; discussion 459.e8-9. 2008
    ..The objective of the study was to determine whether the epidemiology of low-grade ovarian serous cancers is distinct from that of high-grade ovarian serous cancers...
  2. ncbi request reprint Use of psychosocial services increases after a social worker-mediated intervention in gynecology oncology patients
    Yuko Abbott
    Department of Reproductive Medicine, University of California, San Diego, Moores Cancer Center, La Jolla, CA 92093, USA
    Health Soc Work 38:113-21. 2013
    ..The introduction of psychosocial services by a social worker to gynecologic oncology outpatients increases referral rates and expedites evaluation...
  3. doi request reprint Women with gynecologic malignancies have a greater incidence of suicide than women with other cancer types
    Kristy K Ward
    Department of Reproductive Medicine, Division of Gynecologic Oncology, Rebecca and John Moores UCSD Cancer Center, La Jolla, CA 92093 0987, USA
    Suicide Life Threat Behav 43:109-15. 2013
    ..Better understanding of the descriptive epidemiology of suicide among women with gynecologic malignancies could lead to improved risk assessment, screening, and prevention of this potentially avoidable cause of death...
  4. pmc Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression
    Kristy K Ward
    Department of Reproductive Medicine, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA 92093, USA
    Clin Exp Metastasis 30:579-94. 2013
    ..These results support the continued evaluation of FAK inhibitors as a promising clinical treatment for ovarian cancer...
  5. doi request reprint Changing demographics of cervical cancer in the United States (1973-2008)
    Kristy K Ward
    Rebecca and John Moores UCSD Cancer Center, Department of Reproductive Medicine, Division of Gynecologic Oncology, La Jolla, CA, USA
    Gynecol Oncol 126:330-3. 2012
    ..To describe changes in the cervical cancer population...
  6. ncbi request reprint Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study
    Steven C Plaxe
    Department of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA
    Gynecol Oncol 84:32-5. 2002
    ..The Gynecologic Oncology Group (GOG) performed a phase II trial of PZA to determine the response rate of this agent in patients with recurrent platinum-sensitive ovarian cancer...
  7. ncbi request reprint Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study
    Steven C Plaxe
    Department of Reproductive Medicine, Division of Gynecologic Oncology, University of California San Diego Medical Center, 402 Dickinson Street, San Diego, CA 92103 8433, U S A
    Am J Clin Oncol 25:45-7. 2002
    ..Among 24 evaluable patients, there was 1 (4.2%) complete and 1 (4.2%) partial response. The major toxicities were hematologic. With the dose and schedule used, PZA had only modest activity in this population...